International Journal of Diabetes and Metabolism. 2005; 13 (2): 68-75
Dans Anglais
| IMEMR
| ID: emr-70927
ABSTRACT
Diabetic nephropathy [DNP] is a chronic renal disease [CRD] and a major cause of illness and premature death in people with diabetes mellitus [DM]. It is the single most important cause of end-stage renal disease in the Western world and accounts for more than a quarter of all end-stage renal diseases. This article reviews the current development in DNP and the therapeutic challenge with particular reference to the role of calcium channel blockers. Moreover, renal ischaemia hastens the progression of DNP. Diltiazem and amlodipine have a tendency to reverse the changed parameters toward normal values but do not affect the biochemical parameters. Generally speaking, diltiazem is better than amlodipine in reversing biochemical and histopathological changes produced by DNP, and captopril reverses most of the changed parameters with the exception of the histopathological changes. These agents have nephroprotective properties and delay the progression of DNP
Recherche sur Google
Indice:
Méditerranée orientale
Sujet Principal:
Inhibiteurs des canaux calciques
/
Diltiazem
/
Facteurs de risque
/
Amlodipine
/
Complications du diabète
/
Diabète
/
Néphropathies diabétiques
/
Ischémie
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Int. J. Diabetes Metab.
Année:
2005
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS